Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Favorite
Tweet
Print
Gill Low, PhD
Precision for Medicine
Poster(s):
(P 431) INVOKE: A PHASE 1 STUDY OF OKN4395, A FIRST-IN-CLASS EP2/EP4/DP1 TRIPLE PROSTANOID RECEPTOR ANTAGONIST, IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING SARCOMAS
